This is a working overview of melanocortin receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-10-15. Anything still debated is marked as such rather than presented as settled.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analogue of alpha-melanocyte-stimulating hormone |
| Common synonyms | MT-II; melanotan 2 | No internationally accepted non-proprietary name |
| Typical presentation | Lyophilised powder in a sealed vial | Often supplied alongside a separate diluent |
| Regulatory status | Unapproved therapeutic substance | Customs seizure reported in several jurisdictions |
| Reported route in use | Subcutaneous injection | Self-administered outside clinical settings |
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Propranolol is indicated for the treatment of hypertension (high blood pressure). angina pectoris, atrial fibrillation, myocardial infarction, migraine, essential tremor, hypertrophic subaortic stenosis, and pheochromocytoma (catecholamine-secreting tumors). Propranolol is also indicated for the treatment of proliferating infantile hemangioma requiring systemic therapy. Beta blockers were once a first-line treatment for hypertension in the United Kingdom. They were downgraded to fourth-line in 2006 because they do not perform as well as other drugs, particularly in the elderly, and there is increasing evidence that the most common beta blockers at usual doses carry an unacceptable risk of provoking type 2 diabetes. Propranolol is not recommended for the treatment of high blood pressure by the Eighth Joint National Committee (JNC 8) because a higher rate of the primary composite outcome of cardiovascular death, myocardial infarction, or stroke compared to an angiotensin receptor blocker was noted in one study.
=== Deka Base === The Deka Base (デカベース, Deka Bēsu) is the primary headquarters and base of operations of the S.P.D. Earth unit. It is equipped with Base Beams (ベースビーム, Bēsu Bīmu) and houses the Deka Machines. Additionally, the Deka Base can transform into either the Deka Base Crawler (デカベースクローラー, Deka Bēsu Kurōrā), which is equipped with the Crawler Beam (クローラービーム, Kurōrā Bīmu) cannons, or the humanoid Deka Base Robo (デカベースロボ, Deka Bēsu Robo), which is equipped with Finger Missiles (フィンガーミサイル, Fingā Misairu) and Knee Brace Beams (ニーブレスビーム, Nī Buresu Bīmu). Deka Base Robo's finisher is the Volcanic Buster (ヴォルカニック・バスター, Vorukanikku Basutā). As of the direct-to-video anniversary special Tokusou Sentai Dekaranger: 10 Years After, the Deka Base has been rebuilt and renamed the Neo Deka Base (ネオデカベース, Neo Deka Bēsu). As of the direct-to-video anniversary special Tokusou Sentai Dekaranger 20th: Fireball Booster, the Neo Deka Base has been rebuilt and renamed the Shin Neo Deka Base (シン・ネオデカベース, Shin Neo Deka Bēsu).
=== Mergers and acquisitions === In 2019, GoodRx acquired HeyDoctor, a telemedicine company, to integrate virtual healthcare services into the platform. In 2021, a health video content producer, HealthiNation was acquired by GoodRx, which helped provide consumers with health information and offered pharmaceutical manufacturers new ways to reach relevant audiences. In April 2022, GoodRx acquired VitaCare Prescription Services from TherapeuticsMD to strengthen its pharma manufacturer solutions business.
Sources: en.wikipedia.org
Abiotrophy (loss in vitality of organ or tissue) Atrophy (reduced functionality of an organ, with decrease in the number or volume of cells) Hypertrophy (increase in the volume of cells or tissues) Hypotrophy (decrease in the volume of cells or tissues) Dystrophy (any degenerative disorder resulting from improper or faulty nutrition) Pseudohypertrophy (false enlargement of muscle)
Ancient Chinese legend holds that a man named Lao Ai had the largest penis in history and that he had an affair with Queen Dowager Zhao (c. 280–228 BC), the mother of Qin Shi Huang, by pretending to be a eunuch. Ancient Koreans admired large penises and King Jijeung (437–514 AD) of the Silla Dynasty is said to have had a forty-five-centimeter penis that was so large his subordinates had to search for a woman that fit him. Traditional Japanese erotic paintings usually show genitals as exaggeratedly large. The oldest known painting of this type, found in the Hōryū-ji Temple in Ikaruga, dates to the eighth century AD and depicts a fairly large penis.
=== Mass spectral quality === A key feature of this interface is to produce top quality EI spectra from compounds dissolved in a liquid phase. In this case, quality is intended as a measure of the degree of success in a virtual comparison with thousands of spectra stored in the electronic libraries. Identification capability in real-world applications, when peaks are small and noise is high, can be greatly influenced by the quality of ionization. A NIST library version 2.0d was used for comparison. In this case, identification capability is not compromised by the presence of solvent vapor residues and matching quality tops that of a typical GC-MS system.
Sources: en.wikipedia.org
Biopolymers are natural polymers produced by the cells of living organisms. Like other polymers, biopolymers consist of monomeric units that are covalently bonded in chains to form larger molecules. There are three main classes of biopolymers, classified according to the monomers used and the structure of the biopolymer formed: polynucleotides, polypeptides, and polysaccharides. The polynucleotides, RNA and DNA, are long polymers of nucleotides. Polypeptides include proteins and shorter polymers of amino acids; some major examples include collagen, actin, and fibrin. Polysaccharides are linear or branched chains of sugar carbohydrates; examples include starch, cellulose, and alginate. Other examples of biopolymers include natural rubbers (polymers of isoprene), suberin and lignin (complex polyphenolic polymers), cutin and cutan (complex polymers of long-chain fatty acids), melanin, and polyhydroxyalkanoates (PHAs).
Activision introduced the game in May 2003, but in October, Valve experienced a security breach in which hackers stole the source code for Half-Life 2. The breach required new security implementations for the engine, delaying both games; the release of Bloodlines was postponed until early 2005. Until May 2004, Troika and Activision said that the game would feature a multiplayer component and modes, including a team of vampires against a team of vampire hunters, with the ability to upgrade characters between rounds. The team was left without a producer by Activision for over a year before David Mullich was assigned to the project. With no producer oversight, Mullich found the game's design incomplete, game levels created and abandoned, and several technical issues, including problems with code for the proposed multiplayer option. The Source multiplayer code was in its infancy, increasing its development time, and the idea was abandoned. In addition to problems with the Source engine, the designers found that the game's scope exceeded their resources. Bloodlines has several playstyles, requiring different interfaces, animations, and artificial intelligence for stealth, melee combat, and first- or third-person capability. Compared to contemporary first-person shooters, with 10 to 20 animated character models, Bloodlines had over 150 characters with 3,000 unique animations, in addition to boss characters, with their movement styles. The designers underestimated the time required to develop and improve these systems.
Empagliflozin, sold under the brand name Jardiance ( JAR-dee-əns), among others, is an antidiabetic medication used to improve glucose control in people with type 2 diabetes and/or for patients with established heart failure with reduced ejection fraction (HFrEF). Studies have shown great benefits for heart failure (HF) outcomes and decreased hospitalisations. It is taken by mouth. Common side effects of empagliflozin include genital yeast infections and hypotension, particularly in patients with volume depletion. Other symptoms such as nausea and vomiting may occur and seem more pronounced in combination with metformin. Rare but serious adverse events, such as euglycemic diabetic ketoacidosis (DKA) which may present with hyperventilation, lethargy, or mental status changes have been reported but are infrequent in trials. Other serious but rare serious adverse events include Fournier's gangrene, a severe skin infection of the groin, and diabetic ketoacidosis that may occur even with normal blood glucose levels. Use during pregnancy or breastfeeding is not recommended. Empagliflozin is a SGLT2 inhibitor: a reversible inhibitor of the sodium glucose co-transporter-2 (SGLT-2). It reduces the kidney's glucose reabsorption and excretes the excess glucose through the urine, thus its place in the treatment of type two diabetes. It is dependent on blood glucose concentrations and the glomerular filtration rate of the kidney.
In eukaryotes, oxidative phosphorylation occurs in the mitochondrial cristae. It comprises the electron transport chain that establishes a proton gradient (chemiosmotic potential) across the boundary of the inner membrane by oxidizing the NADH produced from the Krebs cycle. ATP is synthesized by the ATP synthase enzyme when the chemiosmotic gradient is used to drive the phosphorylation of ADP. The electrons are finally transferred to exogenous oxygen and, with the addition of two protons, water is formed.
Sources: en.wikipedia.org
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.
It was developed in the 1980s by researchers investigating analogues of alpha-melanocyte-stimulating hormone for pigmentation and related endpoints. Early work included small human studies during the 1990s. Development did not progress to licensing, and the compound remained a research and grey-market item.
Peptides are prone to truncation, oxidation and aggregation during synthesis and handling. Without independent testing, a buyer cannot confirm the identity or the content of a vial. Analytical surveys of unapproved peptide products have repeatedly found discrepancies between label claims and measured composition.
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.